Hello Bloggers! Today, hiv4LIFE have published a good news for all HIV/AIDS patients.
Who is Dr Robert Gallo?: Robert Charles Gallo (born March 23, 1937) is an American biomedical researcher and he is one of the famous scientists who discovered that the (human immunodeficiency virus) HIV virus causes AIDS in 1984 and also pioneered the blood test to detect it. Gallo is also a co-founder of biotechnology company Profectus BioSciences, Inc. and co-founder and scientific director of the Global Virus Network (GVN).
His Career: Dr. Robert Gallo states that his choice of profession was influenced by the early death of his sister from leukemia, a disease to which he initially dedicated much of his research.
One Good News From Dr. Robert Gallo After 31 Years: Now his team at the University of Maryland School of Medicine’s Institute of Human Virology is beginning human trials this month on a potentially revolutionary HIV vaccine. He told Science magazine the vaccine has been in development for 15 years and have seen major breakthroughs on tests using animals, but, like much of the work on AIDS vaccines around the country, it has been a long process.
“The results in monkeys are interesting, but they’re not perfect,” Gallo said at an event at the institute’s Baltimore headquarters to announce the human trial. “If we keep just using monkeys, we’re never going anywhere. We need for humans to respond.” The initial phase the institute is entering this month is designed to make sure the drug is safe for patients and will take about a year. Later phases would test whether the vaccine performs as intended and include more patients than earlier stages. They also would take longer to help ensure there is enough data to support an FDA license. For now, in what the FDA calls a Phase I trial, the institute will enroll 60 people; initially, 20 will get the drug.
The FDA requires a series of increasingly involved human trials before deciding to approve a vaccine for HIV.
Phase I: Tests the safety of a vaccine candidate in up to 100 volunteers for up to two years.
Phase II: Continues testing the safety of a drug candidate and whether it provokes an immune response in several hundred volunteers at risk of acquiring HIV.
Phase IIb: Tests the vaccine’s effectiveness in a larger population of several thousand at-risk individuals. (The combined Phase II trials may last longer than two years.)
Phase III: Tests the vaccine’s effectiveness in at least 10,000 at-risk individuals and monitors for adverse reactions for up to four years.